Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the safety and efficacy of BEY2153 for early Alzheimer's disease, with the study currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• BEY2153 (BEY2153)

Snippet

Sponsor: BeyondBio Inc. | Conditions: Alzheimer Disease, Alzheimer' Disease | Phase 2 | Status: NOT_YET_RECRUITING